Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic invariant natural killer T cells agenT-797

A preparation of allogeneic, off-the shelf, natural killer T cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic iNKT agenT-797, the invariant T-cell receptor (TCR) and natural-killer group 2, member D receptor (NKG2D; KLRK1; natural killer cell activating receptor group 2D) expressed by these cells recognize CD1d-restricted lipid ligands and stress ligands, which are expressed on certain tumor cells. These receptor-ligand interactions may induce the secretion of large amounts of various pro-inflammatory cytokines, including interferon gamma (IFN-g), and activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic iNKT agenT-797
Code name:AGENT 797
AgenT-797
agenT797
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search